AllianceBernstein’s Corvus Pharmaceuticals CRVS Stock Holding History

AllianceBernstein’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$475K	Buy	61,740 +44,620	+261%	+$712K	﹤0.01%	2664
2025 Q4	$132K	Hold	17,120	–	–	﹤0.01%	3145
2025 Q3	$126K	Hold	17,120	–	–	﹤0.01%	3155
2025 Q2	$68.5K	Buy	+17,120	New	+$62.3K	﹤0.01%	3195
2019 Q2	–	Sell	-16,100	Closed	-$65K	–	3155
2019 Q1	$65K	Hold	16,100	–	–	﹤0.01%	3068
2018 Q4	$59K	Hold	16,100	–	–	﹤0.01%	3046
2018 Q3	$138K	Buy	16,100 +800	+5%	+$8K	﹤0.01%	3045
2018 Q2	$168K	Buy	15,300 +1,700	+13%	+$19K	﹤0.01%	3005
2018 Q1	$157K	Hold	13,600	–	–	﹤0.01%	2908
2017 Q4	$141K	Sell	13,600 -900	-6%	-$11.5K	﹤0.01%	2928
2017 Q3	$231K	Hold	14,500	–	–	﹤0.01%	2871
2017 Q2	$175K	Buy	+14,500	New	+$155K	﹤0.01%	3022

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein's CRVS Position: Q1 2026 in Review

AllianceBernstein increased its Corvus Pharmaceuticals (CRVS) stake by 261% in Q1 2026, buying an estimated $712K and bringing the position to 61,740 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

AllianceBernstein first reported a position in CRVS in Q2 2017 and has held it in 12 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

AllianceBernstein held 61,740 shares of Corvus Pharmaceuticals worth $475K as of Q1 2026.
AllianceBernstein bought 44,620 Corvus Pharmaceuticals shares in Q1 2026, an estimated $712K.
Corvus Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2664 holding.
AllianceBernstein first reported a position in Corvus Pharmaceuticals in Q2 2017 and has held it in 12 quarters since.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.